160 results on '"Katagiri, Seiichiro"'
Search Results
2. Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
3. A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02
4. Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study
5. O3-1 HM-SCREEN-Japan 01: a mutation profiling multicenter study on patients with acute myeloid leukemia
6. Clinical utility of genomic profiling of AML using paraffin‐embedded bone marrow clots: HM‐SCREEN‐Japan 01.
7. Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
8. P3-342 - Effectiveness of dose reduced THP-COP like therapy with the addition of etoposide for elderly DLBCL patients
9. Cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab maintenance treatment
10. Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia
11. Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis
12. Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01
13. Genomic Analysis of NPM1 Mutation and KMT2A(MLL)-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01
14. Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01
15. Relevance of diffusion-weighted imaging with background body signal suppression for staging, prognosis, morphology, treatment response, and apparent diffusion coefficient in plasma-cell neoplasms: A single-center, retrospective study
16. Genomic Analysis of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01
17. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib
18. Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01
19. Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML
20. Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome
21. Downregulation of extracellular vesicle microRNA‑101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progression
22. Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
23. Cardiac biopsy with intracardiac echocardiographic guidance for successful diagnosis of cardiac lymphoma
24. Clonal Evolution of Therapy-Related Myeloid Neoplasm Analyzed Sequentially By Targeted Deep Sequencing Using Bone Marrow Cells
25. Effectiveness of dose reduced THP-COP like therapy with the addition of etoposide for elderly DLBCL patients
26. Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
27. Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma
28. Targeting the Hedgehog Signaling Pathway by Glasdegib Limits the Self- Renewal of MDS-Derived Induced Potent Stem Cells (iPSC)
29. Transfusion-transmitted hepatitis E in a patient with myelodysplastic syndromes
30. Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells
31. Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC)
32. Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
33. Targeting the Hedgehog Signaling Pathway By PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms
34. Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
35. ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study
36. Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)
37. Genomic Analysis of FLT3Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01
38. Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms
39. BCL2L11 (BIM) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response
40. Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells
41. Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
42. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
43. Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms
44. Activity Of Omacetaxine Mepesuccinate Against Ponatinib Resistant Philadelphia Chromosome Positive Leukemia Cells
45. High Frequencies Of Switching To 2nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants
46. Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive Leukemia
47. Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells
48. Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms
49. Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells
50. Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.